Paul Belliveau, PharmD

Publications

Peer Reviewed Articles

• Anderson, H., Mommsen, S., Khan, S., Kanaan, A.O., Sullivan, K., Belliveau, P (2023). Medication Safety Management. When an Ounce of Prevention is Worth More Than a Pound of Cure. National Science Teaching Association. https://www.nsta.org/ncss-case-study/medication-safety-management
• Yadav, J. D., Othee, H., Chan, K. A., Man, D. C., Belliveau, P. P., & Towle, J. (2021). Transthyretin Amyloid Cardiomyopathy—Current and Future Therapies. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280211000351
• Durand, C., Bylo, M., Howard, B., & Belliveau, P. (2017). Vancomycin Dosing in Obese Patients: Special Considerations and Novel Dosing Strategies. Annals of Pharmacotherapy. First Published December 21, 2017; https://doi.org/10.1177/1060028017750084.
• Donovan, J.L., Cross, J., Morrill, A.M., Belliveau, P.P., Abel, C.A., Morin, A.K., & Malloy, M.J. (2017). Incorporating the American Pharmacists Association's Delivering Medication Therapy Management services certificate program into an accelerated pharmacy curriculum. Currents in Pharmacy Teaching and Learning, 9, 813-20.
• Mattox, J., Belliveau, P., & Durand, C. (2016). Oritavancin: a novel lipoglycopeptide. Consultant Pharmacist, 31, 86-95.
• Aungst, T.D., & Belliveau, P. (2015). Leveraging mobile smart devices to improve interprofessional communications in inpatient practice setting: A literature review. Journal of Interprofessional Care, 29(6), 570-8.
• Horton, E.R., Morin, A., Pervanas, H.C., Mukherjee, S.M., & Belliveau, P. (2014). A novel structured format for engaging pharmacy students in bioethics discussions. American Journal of Pharmaceutical Education, 78 (9), Article 171. Available from: http://www.ajpe.org/doi/pdf/10.5688/ajpe789171.
• Durand, C., Brueckner, A., Sampadian, C., Willett, K.C., & Belliveau, P. (2014). Daptomycin use in pediatric patients. American Journal of Health-System Pharmacy, 71, 1177-82.
• Morin, A.K., Jarvis, C.I., Pesaturo, K.A., Coppenrath, V., Pervanas, H.C., Cooper, M., Comee, M., & Belliveau, P.P. (2014). Descriptive report of a team-taught elective academic-focused advanced pharmacy practice experience. Currents in Pharmacy Teaching and Learning, 6, 265-276.
• Horton, E.R., & Belliveau, P. (2014). Pediatric pharmacotherapy in the PharmD curriculum: course design and student self-assessment of learning outcomes achievement. Currents in Pharmacy Teaching and Learning, 6, 277-283.
• McDaneld, P.M., Spooner, L.M., Mohr, J.F., & Belliveau, P.P. (2013). Use of Daptomycin to Treat infections with methicillin-resistant staphylococcus aureus isolates having vancomycin minimum inhibitory concentrations of 1.5 to 2 μg/mL. The Annals of Pharmacotherapy, 47, 1654–65.
• Pesaturo, K.A., Horton, E.R., & Belliveau, P.P. (2012). Inhaled aztreonam lysine for cystic fibrosis pulmonary disease-related outcomes. The Annals of Pharmacotherapy, 46, 1076-85.
• Pervanas, H.C., Silva, M.A., Willett, K.C., Cooper, M.R., Durand, C., Belliveau, P., & Abel, C. (2012). Health perception changes of state employees following a health screening event. The Journal of Pharmacy Technology, 28, 47-50.
• Foote, B.S., Spooner, L.M., & Belliveau, P.P. (2011). Boceprevir: A Protease Inhibitor for the Treatment of Chronic Hepatitis C. The Annals of Pharmacotherapy, 45, 1085-93.
• Donovan, J.L., Kanaan, A.O., Silva, M.A., Horton, E., Abel, C., & Belliveau, P.P. (2011). Assessment of center for the advancement of pharmaceutical education (CAPE) outcomes in a capstone course of an accelerated pharmacy program. Currents in Pharmacy Teaching and Learning, 3, 299–306.
• Larson, K.C., Belliveau, P.P., & Spooner, L.M. (2011). Tigecycline for the treatment of severe Clostridium difficile infection. The Annals of Pharmacotherapy, 45, 1005-10.
• Pesaturo, K.A., Spooner, L.M., & Belliveau, P. (2011). Vigabatrin for Infantile Spasms. Pharmacotherapy, 31, 298-311.
• Belliveau, P.P., DeBellis, R.J., Tataronis, G.R., Jarvis, C.I., & Steinberg, M.J. (2010). Assessment of an Elective in Antibacterial Pharmacotherapy. Pharmacy Education, 10, 102-6.
• Lahoz, M.R., Belliveau, P., Gardner, A., & Morin, A. (2010). An Electronic NAPLEX Review Program for Longitudinal Assessment of Pharmacy Students’ Knowledge. American Journal of Pharmaceutical Education, 74 (7), Article 128. Retrieved from: http://www.ajpe.org/doi/pdf/10.5688/aj7407128.
• Allison, G.W., Perla, R.J., Belliveau, P.P., & Angelis, S.M. (2009). Elevated creatine phosphokinase levels associated with linezolid therapy. American Journal of Health-Systems Pharmacy, 66, 1097-1100.
• Mitrano, J.A., Spooner, L.M., & Belliveau, P. (2009). Excretion of antimicrobials used to treat methicillin-resistant Staphylococcus aureus infections during lactation: safety in breastfeeding infants. Pharmacotherapy, 29, 1103-9.
• Gaffney, M.M., Belliveau, P.P., & Spooner, L.M. (2009). Apricitabine: A novel nucleoside reverse transcriptase inhibitor for HIV infection. The Annals of Pharmacotherapy, 43, 1676-83.
• Belliveau, P.P., & Lahoz, M.R. (2007). Treating allergic asthma with omalizumab. Disease Management & Health Outcomes, 15, 165-79.
• Perla, R.J., Knutson, E.L., & Belliveau, P.P. (2007). Emergence of Fluoroquinolone only-resistant Escherichia coli in a community hospital. Clinical Infectious Diseases, 44, 1255.
• Belliveau, P.P, & Perla, R.J. (2007). Antibiogram-derived radial decision trees: innovative visual education tools for discussing empirical antibiotic selections. Pharmacy Education, 7, 43-51.
• Silva, M.S., Matthews, M.L, Jarvis, C., Nolan, N.M., Belliveau, P., Malloy, M., & Gandhi, P. (2007). Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clinical Therapeutics, 29, 253-60.
• Perla, R.J., & Belliveau, P,P. (2005). Antibiotic-derived radial decision trees: an innovative approach to susceptibility data display. American Journal of Infectious Diseases, 1, 124-7.
• Belliveau, P.P, & Lahoz, M.R. (2005). Evaluation of omalizumab from a health plan perspective. Journal of Managed Care Pharmacy, 11, 735-45.
• Belliveau, P.P, & DeBellis, R.J. (2005). Treatment of asymptomatic bacteruria in the noncatheterized hospitalized patient. Reply to Johnson JR. Journal of Clinical Outcomes Management, 12, 406.
• Belliveau, P.P, & DeBellis, R.J. (2005). Management of nosocomial urinary tract infections in adult patients. Journal of Clinical Outcomes Management, 12, 306-14.
• Belliveau, P.P. (2005). Omalizumab: a monoclonal anti-IgE antibody. Medscape General Medicine, 7(1). Retrieved from: http://www.medscape.com/viewarticle/494543.
• Mago, K., Gandhi, P.J., Mazzola, J.L., Belliveau, P.P., Smith, B., Tataronis, G.R., Tran, M., & Saxer, S. (2004). Pharmacist-Assisted Renal Medication Dosing (PHARMD) trial. Pharmacy Journal of New England, 1, 35-9.
• Mazzola, J.L., Belliveau, P.P., & Cheeseman, S.H. (2003). Guidelines for liposomal amphotericin B. American Journal of Health-System Pharmacy, 60, 1480-1.
• Belliveau, P.P. (2002). The impact of concomitant enteral nutrition and feeding tubes on the delivery or fluoroquinolones. Society of Infectious Diseases Pharmacists Newsletter, 12(2), 3-5.
• Belliveau, P.P., Brennan, W.P., & Rothman, A.L. (2000). Levofloxacin use at an academic teaching institution. American Journal of Health-System Pharmacy, 57, 1791-3.
• Belliveau, P. (2000). Systemic pharmacologics for the prevention and treatment of Varicella-Zoster virus infections. University HealthSystem Consortium, 8, 1-70.
• Stirling, A.L., Belliveau, P., Maas, B., Rothman, A., Bercume, R., & Esposito, M. (1999). Experience with a decentralized IV to PO ofloxacin conversion program. Formulary, 34, 688-703.
• Lai, K.K., Kelley, A.L., Melvin, Z.S., Belliveau, P.P., & Fontecchio, S.A. (1998). Failure to eradicate vancomycin-resistant enterococci in a university hospital and the cost of barrier precautions. Infection Control and Hospital Epidemiology, 19, 647-652.
• Freeman, C.D., Nicolau, D.P., Belliveau, P.P., & Nightingale, C.H. (1997). Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. Journal of Antimicrobial Chemotherapy, 39, 677-86.
• Belliveau, P.P., Freeman, C.D., Nicolau, D.P., Nightingale, C.H., Tessier, P.R., & Quintiliani, R. (1996). Bactericidal activity of ceftizoxime and ceftriaxone against pathogens associated with community- and nosocomial-acquired pneumonia. American Journal of Health-System Pharmacy, 53, 1024-7.
• Belliveau, P.P., Rothman, A.R., & Maday, C.E. (1996). Limiting vancomycin use to combat vancomycin-resistant Enterococcus faecium. American Journal of Health-System Pharmacy, 53, 1570-5
• Klepser, M.E., Zhu, Z., Nicolau, D.P., Banevicius, M.A., Belliveau, P.P., Ross, J.W., Broisman, L., Quintiliani, R., & Nightingale, C.H. (1996). Oral absorption of trimethoprim-sulfamethoxazole in patients with AIDS. Pharmacotherapy, 16, 656-62.
• Lai, K.K., Kleinjan, J., & Belliveau, P. (1996). Vancomycin-induced neutropenia treated with granulocyte colony-stimulating factor during home intravenous infusion therapy. Clinical Infectious Diseases, 23, 844-5.
• Nicolau, D.P., Freeman, C.D., Belliveau, P.P., Nightingale, C.H., Ross, J.W., & Quintiliani, R. (1995). Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrobial Agents and Chemotherapy, 39, 650-5.
• Belliveau, P.P. Once-daily aminoglycoside dosing. (1995). Therapeutic Drug Monitoring and Toxicology In-Service Training and Continuing Education, 16, 93-8.
• Belliveau, P.P., Nightingale, C.H., & Quintiliani, R. (1995). Stability of cefotaxime sodium and metronidazole 0.9% sodium chloride injection or in ready-to-use metronidazole bags. American Journal of Health-System Pharmacy, 52, 1561-3.
• Nicolau, D.P., Belliveau, P.P., Nightingale, C.H., Quintiliani, R., & Freeman, C.D. (1995). Implementation of a once-daily aminoglycoside program in a large community-teaching hospital. Hospital Pharmacy, 30, 674-6,679-80.
• Nightingale, C.H., Belliveau, P.P., & Quintiliani, R. (1995). Cost issues and considerations when choosing antimicrobial agents. Infectious Diseases in Clinical Practice, 4 (Suppl 2), S64-7.
• Belliveau, P.P., Nicolau, D.P., Nightingale, C.H., & Quintiliani, R. (1995). Once-daily gentamicin: experience in one hundred eighteen patients with postpartum endometritis. Journal of Infectious Disease Pharmacotherapy, 1, 11-8.
• Patel, K.B., Belliveau, P.P., Nightingale, C.H., Nicolau, D.P., & Quintiliani R. (1995). Absorption of ciprofloxacin in febrile and afebrile patients. The International Journal of Antimicrobial Agents, 6, 119-22.
• Nightingale, C.H., Belliveau, P.P., & Quintiliani R. (1994). Cost issues and considerations when choosing antimicrobial agents. Infectious Diseases in Clinical Practice, 3, 8-11.
• Belliveau, P.P., Nightingale, C.H., & Quintiliani, R. (1994). Stability of aztreonam and ampicillin sodium-sulbactam sodium in 0.9% sodium chloride injection. American Journal of Hospital Pharmacy, 51, 901-4.
• Freeman, C.D., Nightingale, C.H., Nicolau, D.P., Belliveau, P.P., Tessier, P.R., Fu, Q., Xuan, D., & Quintiliani, R. (1994). Bactericidal activity of low-dose ceftizoxime plus metronidazole compared with cefoxitin and ampicillin-sulbactam. Pharmacotherapy, 14, 185-90.
• Freeman, C.D., Nightingale, C.H., Nicolau, D.P., Belliveau, P.P., & Quintiliani R. (1994). Serum bactericidal activity of ceftriaxone plus metronidazole against common pathogens of intraabdominal infection. American Journal of Hospital Pharmacy, 51, 1782-7.
• Belliveau, P.P., Nightingale, C.H., Quintiliani, R., & Maderazo, E.G. (1994). Reduction in serum concentrations of ciprofloxacin secondary to ursodiol in a patient with hepatobiliary disease. Clinical Infectious Diseases, 19, 354-5.
• Freeman, C.D., Nightingale, C.H., Nicolau, D.P., Belliveau, P.P., Banevicius, M.A., & Quintiliani, R. (1994). The intracellular and extracellular penetration of azithromycin into inflammatory and noninflammatory blister fluid. Antimicrobial Agents and Chemotherapy, 38, 2449-51.
• Nightingale, C.H., Belliveau, P.P., & Quintiliani, R. (1994). Conversion of intravenous to oral ciprofloxacin: observing the "like-to-like" phenomenon. In: Garrard C, editor. Ciprofloxacin i.v. Defining its role in serious infections. Proceedings of an International Symposium; 1993 Sept; Salzburg (Germany). Berlin (Germany):Springer-Verlag, 85-95.
• Nightingale, C.H., Belliveau, P.P., Nicolau, D.P., & Quintiliani R. (1994). Streamlining antibiotic therapy in the hospital setting: cost containment by switching from parenteral to oral therapy. Proceedings of the 4th Western Pacific Congress on Chemotherapy and Infectious Diseases; 1994 Dec 4-7; Manila (Philippines). Journal of the American Medical Association Southeast Asia, 10, suppl, 373-8.
• Quintiliani, R., Nightingale, C.H., Belliveau, P., & Sullivan, M. (1993). A new cost-effective option. Cefotaxime plus metronidazole for intra-abdominal infection. Pharmacy and Therapeutics, 18, 277-9.
• Belliveau, P.P., Shea, B.F., & Scavone, J.M. (993). Stability of metoprolol tartrate in 5% dextrose injection or 0.9% sodium chloride injection. American Journal of Hospital Pharmacy, 50, 950-2.
• Belliveau, P., Hickingbotham, N., Maderazo, E.G., Mazens-Sullivan, M., & Robinson, A. (1993). Institution-specific patterns of infection and Gram's stain as guides for empiric treatment of patients hospitalized with typical community-acquired pneumonia. Pharmacotherapy, 13, 396-401.
• Freeman, C.D., Nicolau, D.P., Belliveau, P.P., & Nightingale, C.H. (1993). Lomefloxacin clinical pharmacokinetics. Clinical Pharmacokinetics, 25, 6-19.
• Belliveau, P., Nightingale, C.H., Quintiliani, R., Crowe, H., & Gousse, G. (1993). Oral ciprofloxacin, ofloxacin and lomefloxacin as alternatives to intravenous antimicrobial therapy. Connecticut Medicine, 57, 539-45.
• Belliveau, P. (1992). Ofloxacin vs ciprofloxacin: a comparison. Connecticut Medicine, 56, 261-63.
• Belliveau, P. (1991). Cyclobenzaprine (Flexeril®). Clinical Toxicology Review, 13, 1-2.